ANU Stock Chart & Stats
0.81
0.04(4.76%)
―
--
Day’s Range― - ―
52-Week Range0.74 - 2.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)125.00
Market Cap
€1.49M
Enterprise Value2.52M
Total Cash (Recent Filing)€992.85K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding1,816,565
10 Day Avg. Volume2
30 Day Avg. Volume125
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.28
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.56
Revenue Forecast (FY)€2.89M
Bulls Say, Bears Say
Bulls Say
Regulatory Pipeline ProgressThe planned Health Canada CTA and parallel U.S. strategy show that XORTX is advancing XRx-026 through defined regulatory milestones. If execution continues, the approach could accelerate clinical data generation, support future filings, and broaden access to the company’s proprietary oxypurinol formulation.
Clinical And Commercial ReadinessStarting GMP substance production and commercial-scale tablet manufacturing moves XORLO beyond an early laboratory concept toward trial supply and potential commercialization. The resulting validation and stability data may support regulatory submissions and improve readiness if clinical outcomes remain favorable.
Low Financial LeverageMinimal leverage reduces fixed financial obligations and avoids the interest and refinancing pressures often faced by development-stage companies. This provides some balance-sheet flexibility while XORTX advances its pipeline, although it does not eliminate the need to fund ongoing research and operations.
Bears Say
No Commercial RevenueThe absence of revenue confirms that XORTX has not yet established a commercial earnings base and remains dependent on successful development and future approvals. Persistent losses limit internally generated funding and leave the company exposed to continued operating and commercialization uncertainty.
Persistent Cash BurnSustained operating and free-cash-flow deficits mean XORTX consumes cash while its programs remain in development. Continued external funding is therefore required to sustain operations, creating financing risk and potentially constraining the pace or scope of clinical and regulatory activities.
Clinical Execution And Manufacturing DependenceXORTX’s path to approval depends on successful clinical results, regulatory progress, and execution of manufacturing activities involving a commercial partner. These dependencies create material development risk because failure at any stage could delay the planned NDA pathway and postpone potential revenue generation.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was 0.74 and its highest was 2.81 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €1.49M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 18 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Aug 15, 2026. The company reported -0.937 earnings per share for the quarter.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Undervalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -0.937 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.